Sandra Lechner received her BS in Chemistry/Biology from West Chester University and her PhD in Physiology/Pharmacology from the University of California, San Diego, where she worked with Ron Kuczenski and David Segal, examining the behavioral and neurochemical correlates of stimulant addiction. She completed a postdoctoral fellowship at Hahnemann University where she worked with Rita Valentino and studied CRF and the neurobiology of stress. Since her postdoctoral work, Dr. Lechner has been involved in neuroscience research in the biotech and pharmaceutical industry, holding positions as Group Leader, Behavioral Pharmacology at Allelix Neuroscience, where she worked on projects targeting the treatment of schizophrenia, pain and spasticity; Group Leader, Histology/Imaging at Merck Research Laboratories, where she established a core histology/imaging group for the analysis of CNS targets; and currently Director, Neuroscience at Neurocrine Biosciences, where she has primarily worked in the area of Parkinson’s disease and has served as Project Leader for the A2A Antagonist Program.